Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DSP107 in advanced solid tumors
NCT04440735Phase 2Active, not recruiting
- Sponsor
- KAHR Medical
- Start
- Oct 2020
- Primary completion
- Sep 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of DSP107 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (5 arms), sponsored by KAHR Medical. Primary endpoints: Adverse Events at 9 months, Dose Limiting Toxicities at 21 days and 1 more. Started Oct 2020; status: active, not recruiting.
02
Drugs
DSP107
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04440735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04440735.